Analyst James Orsborne of Stifel Nicolaus maintained a Buy rating on Futura Medical (FUM – Research Report), with a price target of p140.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
James Orsborne has given his Buy rating due to a combination of factors including Futura Medical’s strong financial performance and strategic advancements. The company reported a significant increase in revenues to £13.9 million, surpassing market expectations and marking a 349% rise compared to the previous year. Additionally, Futura achieved profitability for the first time, with earnings of £1.3 million, and ended the year with a solid cash balance of £6.6 million, ensuring sufficient working capital through the second half of 2026.
Moreover, Futura Medical has made substantial progress in its business operations, notably with the successful launch of Eroxon in the US and over 15 other countries. The company has also advanced its research and development efforts, yielding positive results in its product pipeline. Despite some challenges anticipated in 2025, such as slower-than-expected market roll-outs, the overall outlook remains positive, justifying the Buy rating by highlighting the company’s potential for long-term growth.